Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kuffel

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humansJoel M Reid, Mary J Kuffel, Stacie L Ruben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factorR M Goldberg, J M Reid, M M Ames, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 21, 2012
Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agentsDavid E Zembower, Yongping Xie, Ali Koohang, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2010
Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in ratsJoel M Reid, Sarah A Buhrow, Mary J Kuffel, et al.
Investigational New Drugs|September 1, 2005
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trialEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Pharmacogenomics|October 4, 2011
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifenAnn M Moyer, Vera J Suman, Richard M Weinshilboum, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Nature Communications|May 21, 2026
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase CβAnh T Q Cong, Taylor L Witter, Elizabeth S Bruinsma, et al.
NPJ Breast Cancer|December 19, 2023
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancerSwaathi Jayaraman, Xinyan Wu, Krishna R Kalari, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humansJoel M Reid, Mary J Kuffel, Stacie L Ruben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factorR M Goldberg, J M Reid, M M Ames, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 21, 2012
Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agentsDavid E Zembower, Yongping Xie, Ali Koohang, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2010
Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in ratsJoel M Reid, Sarah A Buhrow, Mary J Kuffel, et al.
Investigational New Drugs|September 1, 2005
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trialEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Pharmacogenomics|October 4, 2011
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifenAnn M Moyer, Vera J Suman, Richard M Weinshilboum, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Nature Communications|May 21, 2026
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase CβAnh T Q Cong, Taylor L Witter, Elizabeth S Bruinsma, et al.
NPJ Breast Cancer|December 19, 2023
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancerSwaathi Jayaraman, Xinyan Wu, Krishna R Kalari, et al.
Pageof 3